Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aripiprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 20/20 | 1.00 |
| ▸ | HTR1A known ✓ | P08908 | 3/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 1.00 |
| ▸ | DRD3 | P35462 | 5/20 | 1.00 |
| ▸ | DRD4 | P21917 | 4/20 | 1.00 |
| ▸ | HTR2B | P41595 | 3/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | DRD5 | P21918 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | HTR7 | P34969 | 2/20 | 1.00 |
| ▸ | HTR6 | P50406 | 2/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | HTR3B | O95264 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aripiprazole SCHEMBL29356997 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL8255 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL29475637 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL29475638 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL982189 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL7097505 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL236666 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL5147095 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL30958766 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL31174198 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179064-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | AUSPEX PHARMACEUTICALS LLC | 2025-06-05 | — | — | US | claimed |
| CN-222829169-U | Disc type melt filter for preventing resin melt from generating gel | 康辉南通新材料科技有限公司 | 2025-05-06 | — | — | CN | claimed |
| CN-222837332-U | Combined crucible for carbon ceramic brake disc melt siliconizing | 山东道普安制动材料有限公司 | 2025-05-06 | — | — | CN | claimed |
| EP-4125903-B1 | METHODS FOR DOSE INITIATION OF ARIPIPRAZOLE TREATMENTS | OTSUKA PHARMA CO LTD (JP) | 2024-10-09 | — | — | EP | claimed |
| CN-118706999-A | Method for detecting concentration of antipsychotic in serum | 南宁市社会福利医院(南宁市精神病爱心医院) | 2024-09-27 | — | — | CN | claimed |
| CN-221680984-U | Carbon ceramic brake disc fusion siliconizing device | 江西杰途新材料有限公司 | 2024-09-10 | — | — | CN | claimed |
| CN-117401986-A | Carbon ceramic brake disc fusion siliconizing device and method | 崇义恒毅陶瓷复合材料有限公司 | 2024-01-16 | — | — | CN | claimed |
| US-20240000810-A1 | USE OF CANNABINOIDS IN THE TREATMENT OF TOURETTE SYNDROME AND TIC DISORDERS | Orcosa Inc. (US) | 2024-01-04 | — | — | US | claimed |
| CN-108707987-B | Spinning assembly for bicomponent fibers | 苏州金泉新材料股份有限公司 | 2023-06-27 | — | — | CN | claimed |
| US-20260144782-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | AUSPEX PHARMACEUTICALS LLC (US) | 2026-05-28 | — | — | US | disclosed |
| US-20260137673-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | AUSPEX PHARMACEUTICALS LLC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260115135-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | AUSPEX PHARMACEUTICALS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260115134-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | AUSPEX PHARMACEUTICALS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20260049978-A1 | METHODS FOR TREATING CAG REPEAT EXPANSION DISORDERS USING SMALL MOLECULES THAT SELECTIVELY REDUCE EXPANDED CAG TRANSCRIPT LEVELS | UNIV NEW YORK STATE RES FOUND (US) | 2026-02-19 | — | — | US | disclosed |
| US-11357772-B2 | Methods for the treatment of abnormal involuntary movement disorders | AUSPEX PHARMACEUTICALS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| WO-2022105810-A1 | RESORCINOL COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF IN NERVOUS SYSTEM DISEASES | 中国科学院上海药物研究所 | 2022-05-27 | — | — | WO | disclosed |
| EP-3182958-B2 | ARIPIPRAZOLE PRODRUG COMPOSITIONS | ALKERMES PHARMA IRELAND LTD (IE) | 2022-05-18 | — | — | EP | disclosed |
| CN-108471762-B | Processed cheese formula products with improved melt and firmness and methods of manufacture | 卡夫食品集团品牌有限责任公司 | 2022-05-03 | — | — | CN | disclosed |
| US-20220079939-A1 | ARIPIPRAZOLE PRODRUG COMPOSITION | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2022-03-17 | — | — | US | disclosed |
| US-20220064143-A1 | PROCESS FOR THE PREPARATION OF ARIPIPRAZOLE LAUROXIL | INTERQUIM, S.A. (ES) | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049978-A1 | METHODS FOR TREATING CAG REPEAT EXPANSION DISORDERS USING SMALL MOLECULES THAT SELECTIVELY REDUCE EXPANDED CAG TRANSCRIPT LEVELS | HTT, SMN1; SMN2, FUS | DRD2 1915/4885HTR1A 1287/4885HTR2A 1003/4885 |
| US-20250179064-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | ACAT2, CPT1A, SLC18A2 | DRD2 2127/4885HTR1A 747/4885HTR2A 501/4885 |
| US-11357772-B2 | Methods for the treatment of abnormal involuntary movement disorders | CKMT1A; CKMT1B, GYS1, MUSK | DRD2 425/4885HTR1A 316/4885HTR2A 247/4885 |
| US-20220064143-A1 | PROCESS FOR THE PREPARATION OF ARIPIPRAZOLE LAUROXIL | CYP2F1, CYP4F8, CYP3A4 | DRD2 1196/4885HTR1A 195/4885HTR2A 410/4885 |
| US-20260144782-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | DRD2, HTR2C, SLC18A2 | DRD2 1/4885HTR1A 18/4885HTR2A 10/4885 |
| US-20220079939-A1 | ARIPIPRAZOLE PRODRUG COMPOSITION | CYP2D6, CYP2B6, CYP2A6 | DRD2 389/4885HTR1A 313/4885HTR2A 229/4885 |
| US-20260115134-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | HTR1D, HTR5A, PCNP | DRD2 74/4885HTR1A 8/4885HTR2A 39/4885 |
| US-20260115135-A1 | NOVEL PHARMACEUTICAL FORMULATIONS | FLNB, SETD1B, HTR5A | DRD2 62/4885HTR1A 51/4885HTR2A 40/4885 |
| US-20260137673-A1 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | HTT, HTR2C, NSD1 | DRD2 14/4885HTR1A 23/4885HTR2A 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.